Articles related to PROSTATE CANCER

The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate cancer patients.

A discussion between an oncologist and a patient, Evelyn, a transgender woman with prostate cancer who was able to change the doctor’s binary view of gender thanks to a candid conversation and the help from a dozen eggs – brown and blue.

Published on the AUA website and developed by a panel of experts from these three groups as well as representation from the American Society of Clinical Oncology (ASCO) and a patient advocate, 38 recommendations are listed across the care continuum of advanced disease.

Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.